Sepsis Treatment Research Report 2017: Quantitative, Objective Data Focused on the Treatment of Sepsis Requiring Hospitalization - Research and Markets

DUBLIN--()--The "Sepsis - Treatment Report" report has been added to Research and Markets' offering.

This report is part two of a two-part series on hospital-treated sepsis. This report provides quantitative, objective data focused on the treatment of sepsis requiring hospitalization captured by hospitals contributing to Cerner Health Facts. This data provides real-world patient encounters and reflects real physician decisions and encounter characteristics (e.g. patient response to therapy and outcomes) in key areas, such as antimicrobial stewardship.

Sepsis is responsible for an estimated 12% of all hospital stays. At an average cost of $15,500 per occurrence, we estimate that hospitalizations for severe infections account for $212 billion in annual spending or 7% of total healthcare expenditure. In this report, we conduct an in-depth analysis of sepsis patient characteristics, medication management, costs, and laboratory testing.

Gram-positive bacteria are the likely causative agents of most sepsis infections. Physicians treat the vast majority of these infections with vancomycin, piperacillin-tazobactam, levofloxacin, and ceftriaxone. After confirmatory diagnosis, over half of sepsis patients undergo a change in antibiotic therapy.

Key Topics Covered:

1. Patient Flow

2. Executive Summary

3. Incidence and Impact of Disease

  • Incidence
  • Length of Stay
  • Total Cost

4. Patient Demographics

  • Age
  • Insurance type
  • Gender
  • Region
  • Mortality
  • Comorbid Conditions

5. Patient Flow through the Hospital

  • Admission Site
  • Lab Testing
  • Lab TAT
  • Results
  • Etiology
  • Empiric Therapy
  • Change in treatment

6. Drug Share for Key Therapeutics

  • Most Common
  • LOS
  • APACHE Score
  • Treatment Duration
  • Product Dashboards

7. Outcomes of Treatment

  • Antibiotic Usage
  • Mortality
  • Cost per Patient

8. Database Overview

9. Methodology

For more information about this report visit https://www.researchandmarkets.com/research/lps4gx/sepsis

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Infectious Diseases Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Infectious Diseases Drugs